Related Experiment Video
Updated: Nov 17, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor
Sara Parsa1, Ana Ortega-Molina1, Hsia-Yuan Ying2
1Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract:
Cancer cells adapt their metabolic activities to support growth and proliferation. However, increased activity of metabolic enzymes is not usually considered an initiating event in the malignant process. Here, we investigate the possible role of the enzyme serine hydroxymethyltransferase-2 (SHMT2) in lymphoma initiation. SHMT2 localizes to the most frequent region of copy number gains at chromosome 12q14.1 in lymphoma. Elevated expression of SHMT2 cooperates with BCL2 in lymphoma development; loss or inhibition of SHMT2 impairs lymphoma cell survival. SHMT2 catalyzes the conversion of serine to glycine and produces an activated one-carbon unit that can be used to support S-adenosyl methionine synthesis. SHMT2 induces changes in DNA and histone methylation patterns leading to promoter silencing of previously uncharacterized mutational genes, such as SASH1 and PTPRM. Together, our findings reveal that amplification of SHMT2 in cooperation with BCL2 is sufficient in the initiation of lymphomagenesis through epigenetic tumor suppressor silencing.
Insights
Amplification of serine hydroxymethyltransferase-2 (SHMT2) cooperates with BCL2 to initiate lymphoma. SHMT2 promotes epigenetic silencing of tumor suppressors, driving lymphomagenesis.
Area of Science:
- Oncology
- Cancer Metabolism
- Epigenetics
Background:
- Cancer cells exhibit altered metabolism for growth.
- Metabolic enzyme activity is rarely considered a primary driver of cancer.
- The role of serine hydroxymethyltransferase-2 (SHMT2) in lymphoma initiation is unexplored.
Purpose of the Study:
- To investigate the role of SHMT2 in lymphoma initiation.
- To understand the mechanism by which SHMT2 contributes to lymphomagenesis.
Main Methods:
- Analysis of SHMT2 localization to chromosome 12q14.1 in lymphoma.
- Investigating the cooperation between SHMT2 and BCL2 in lymphoma development.
- Assessing the impact of SHMT2 loss or inhibition on lymphoma cell survival.
- Examining SHMT2's role in DNA and histone methylation patterns.
Main Results:
- SHMT2 is located at chromosome 12q14.1, a region with frequent copy number gains in lymphoma.
- Elevated SHMT2 expression collaborates with BCL2 to promote lymphoma.
- SHMT2 inhibition or loss reduces lymphoma cell survival.
- SHMT2 alters DNA and histone methylation, silencing tumor suppressor genes like SASH1 and PTPRM.
Conclusions:
- SHMT2 amplification, in conjunction with BCL2, is sufficient for initiating lymphomagenesis.
- SHMT2 drives lymphoma initiation by epigenetically silencing tumor suppressor genes.
More Related Videos
10:33Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...